SCHEMBL31269346

SCHEMBL31269346

CNC(=O)COc1ccc(-c2nc3c(OC4(C)CC4)ncnc3n2Cc2cc(Cl)ccn2)c(Cl)c1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PIK3CD O00329 2/20 0.34
▸ KCNH2 Q12809 4/20 0.32
▸ CNR1 P21554 4/20 0.32
▸ ACACB O00763 1/20 0.31
▸ MCHR1 Q99705 1/20 0.31
▸ PDK2 Q15119 1/20 0.31
▸ PKM P14618 1/20 0.31
▸ PRKAB2 O43741 1/20 0.31
▸ PRKAG1 P54619 1/20 0.31
▸ PRKAA2 P54646 1/20 0.31
▸ PRKAA1 Q13131 1/20 0.31
▸ PRKAG3 Q9UGI9 1/20 0.31
▸ PRKAG2 Q9UGJ0 1/20 0.31
▸ PRKAB1 Q9Y478 1/20 0.31
▸ SYK P43405 1/20 0.30
▸ POLB P06746 1/20 0.30
▸ SENP2 Q9HC62 1/20 0.30
▸ P2RX3 P56373 1/20 0.30
▸ HDAC8 Q9BY41 1/20 0.30
▸ HDAC6 Q9UBN7 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31268824 0.94 PIK3CD (0.34) PIK3CDKCNH2PDK2PKMPRKAB2
SCHEMBL30983512 0.89 KMT2A (0.36) PIK3CDCNR1PDK2PRKAB2PRKAG1
SCHEMBL31268841 0.87 CNR1 (0.33) PIK3CDKCNH2CNR1
SCHEMBL31269351 0.87 PIK3CD (0.35) PIK3CDKCNH2CNR1
SCHEMBL31269267 0.87 CNR1 (0.32) PIK3CDKCNH2CNR1
SCHEMBL31269005 0.86 PDE2A (0.35) PIK3CDKCNH2CNR1
SCHEMBL31268974 0.86 ALDH1A1 (0.35) PIK3CDKCNH2CNR1
SCHEMBL31268819 0.86 PIK3CD (0.36) PIK3CDKCNH2
SCHEMBL30983885 0.86 CNR1 (0.33) PIK3CDKCNH2CNR1
SCHEMBL31269423 0.85 PIK3CD (0.37) PIK3CDPDK2PRKAB2PRKAG1PRKAA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4689155-A1 USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS Astrazeneca AB (SE) 2026-02-11 — — EP disclosed
WO-2024201368-A1 USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS ASTRAZENECA AB (SE) 2024-10-03 — — WO disclosed
Send feedback